Quoin Pharmaceuticals, Ltd. (QNRX) Revenue History
Annual and quarterly revenue from 2015 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
QNRX Revenue Growth
QNRX Revenue Analysis (2015–2025)
As of May 8, 2026, Quoin Pharmaceuticals, Ltd. (QNRX) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue.
Looking at the longer-term picture, QNRX's historical revenue data shows various trends over time.
When compared to Healthcare sector peers including RARE (+13.3% YoY), FOLD (+20.0% YoY), and PTCT (-53.3% YoY). Compare QNRX vs RARE →
QNRX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| QNRXCurrent | $0 | - | - | - | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% | |
 PTCT | $1.7B | -53.3% | +35.4% | 49.5% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% |
QNRX Historical Revenue Data (2015–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $-100,793 | - | $-16,419,949 | - |
| 2024 | $0 | - | $0 | - | $-9,528,465 | - |
| 2023 | $0 | - | $0 | - | $-9,378,504 | - |
| 2022 | $0 | - | $0 | - | $-9,257,704 | - |
| 2021 | $0 | - | $0 | - | $-6,062,850 | - |
| 2020 | $0 | - | $0 | - | $-1,670,010 | - |
| 2019 | $0 | +100.0% | $-227,055 | - | $-1,560,401 | - |
| 2018 | $-280,000 | - | $-405,720 | 144.9% | $15.3M | -5470.4% |
| 2017 | $0 | +100.0% | $-104,223 | - | $10.2M | - |
| 2016 | $-280,000 | - | $-369,130 | 131.8% | $15.3M | -5470.4% |
See QNRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs QNRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare QNRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonQNRX — Frequently Asked Questions
Quick answers to the most common questions about buying QNRX stock.
Is QNRX's revenue growth accelerating or slowing?
QNRX TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is QNRX's long-term revenue growth rate?
Quoin Pharmaceuticals, Ltd.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is QNRX's revenue distributed by segment?
QNRX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2015-2025 are available for download. Segment mix reveals concentration and diversification trends.